- Home
- INNV vs CTNM Comparison
INNV vs CTNM Comparison
Compare INNV & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INNV | CTNM |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 416.1M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | INNV | CTNM |
|---|---|---|
| Price | $5.82 | $11.96 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $18.60 |
| AVG Volume (30 Days) | 113.1K | ★ 255.0K |
| Earning Date | 02-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $884,662,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $2.60 | $3.35 |
| 52 Week High | $6.26 | $13.49 |
Technical Indicators
Market Signals| Indicator | INNV | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 58.06 |
| Support Level | $5.21 | $8.92 |
| Resistance Level | $5.86 | $11.90 |
| Average True Range (ATR) | 0.29 | 0.92 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 75.61 | 79.84 |
Price Performance
Historical ComparisonAbout INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.